Is the CSL (ASX:CSL) share price a buy today?

CSL shares have fallen almost 10%, could it be a good one buy?

| More on:
CSL share price Digitised bubbles of cells representing ASX biotech shares such as CSL

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The CSL Limited (ASX: CSL) share price has fallen around 10% over the last couple of weeks. Could the healthcare giant be a good one to consider for the long-term?

What does the business do?

This is a global biotechnology business that is headquartered in Melbourne. It aims to save lives and protect the health of people who were stricken with a range of serious and chronic medical conditions.

CSL says it develops and delivers innovative biotherapies and influenza vaccines.

Research and development is an important part of the picture for CSL. It has spent US$4.1 billion on R&D investments in the last five years to develop its product pipeline. It has more than 1,700 people committed to its R&D team.

Blood plasma collection is another sizeable element of the business. It has 300 centres across China, Europe and North America.

Do brokers rate the CSL share price as a buy?

There are differing opinions about the healthcare giant.

For example, Credit Suisse has a neutral rating on CSL, with a price target of $315. The broker notes that competition is rising from competitors, which makes it harder for CSL's longer-term growth because of how new plasma collection locations are an important driver for growth. However, it still thinks it can grow profit in the coming years.

Credit Suisse puts the CSL share price at 38x FY23's estimated earnings.

However, Morgans is a bit more positive on the business, with a price target of $324.40 for the CSL share price. The performance of Seqirus was a key feature from the FY21 result for the broker.

FY21 result and FY22 outlook

In constant currency terms, CSL reported 10% growth of both revenue and net profit. The business generated US$2.375 billion of net profit.

Management highlighted that critical operations were maintained during the worst points of the COVID-19 pandemic, demonstrating CSL's resilience and agility. The new distribution model is fully operational in China with sales of albumin now normalised.

Seqirus, the vaccine business, saw total revenue growth of 30%, with seasonal influenza vaccine sales up 41%.

It said that new and extended influenza pandemic agreements had been reached. It also said that the next generation influenza vaccine facility is going to be constructed in Australia.

With its outlook, CSL warned that its margin was easing as a result of increased plasma costs. It sees FY22 as a transitional year as it continues to invest for its long-term strategy.

In FY22 it's expecting to generate net profit of between US$2.15 billion to $2.25 billion in constant currency terms.

What's the market capitalisation at the current CSL share price?

At the current CSL share price, it has a market capitalisation of $131 billion according to the ASX.

Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of and has recommended CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Female pharmacist smiles with a digital tablet.
Healthcare Shares

Are Wesfarmers or Sigma shares a better buy in the pharmacy arena?

These two stocks are both leaders in the industry.

Read more »

A young man goes over his finances and investment portfolio at home.
Healthcare Shares

Down 20%, is the NIB share price undervalued?

Here's what Goldman Sachs is saying about this blue chip stock.

Read more »

four excited doctors with their hands in the air
Healthcare Shares

Sigma Healthcare shares rocket 39% on Chemist Warehouse merger approval

The ACCC doesn't believe the company's merger with Chemist Warehouse will lessen competition.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

ASX 200 healthcare stock rockets on $75 million news

This marks another positive step for the company.

Read more »

Male doctor in a lab coat working at laptop looking serious.
Healthcare Shares

CSL shares are in the red for 2024. Are they a buy?

Meanwhile, the broader market has extended to new highs this year.

Read more »

A smiling businessman in the city looks at his phone and punches the air in celebration of good news.
Share Market News

Guess which ASX 300 stock is jumping 11% on big news

Big news is giving this stock an even bigger lift on Tuesday. What's happening?

Read more »

Two lab workers fist pump each other.
Healthcare Shares

Guess which ASX 200 healthcare stock is starting the week with a bang on big news!

What is getting investors excited today? Let's find out.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

3 small-cap ASX healthcare shares 'with strong prospects'

Fund manager IML discusses why these 3 ASX healthcare shares are likely to rise in value.

Read more »